- Corporate Group
- News
- Contact Us
Search
News
2025-11-21
TW Patent No. I905962 entitled COMPOUND FOR CONJUGATION, CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME was granted on Nov 21, 2025.
2025-11-12
Formosa Laboratories and Easywell Biomedicals Partner to Develop TLX-054 Injectable and Strengthen High-Value Drug Portfolio
Formosa Laboratories entered into a strategic partnership with Easywell Biomedicals, Inc. to jointly develop the TLX-054 injectable formulation. Through this collaboration, both parties will leverage their respective core expertise and resources to further strengthen the injectable product portfolios and expand into high-value and complex drug markets.
2025-10-08
Formosa Laboratories received EU-GMP API and Injectable manufacturing certification from the health authority of Poland.
2025-07-14
In addition to Cytotoxic Liquid dosage forms, the GMP certificate of Formosa Labs' injectable plant nowincludes Biotechnology products as freeze-dried powder by aseptic preparation following a successful GMP inspection by TFDA. (July 03, 2025)
2025-02-14
Filed US DMF of Abemaciclib (#041250, date of submission: Jan. 24, 2025)
2024-11-21
Passed 6th on-site GMP inspection for Alfacalcidol by PMDA of Japan.
2024-11-05
Formosa Labs and a US pharmaceutical company with over 50 years of experience have signed a licence and supply agreement for a breast cancer chemotherapy injection.
2024-09-16
Passed the 9th US FDA inspection, including API and our high-potent injectable facilities.
2024-06-13
Formosa Laboratories Completes the Acquisition of Synchem to Expand North American CDMO Footprint
2023-12-28
TFDA’s inspection on our new Plant H, with expanded capacity for polymer products.
2023-08-25
US Patent No.US11,731,998 B2 entitled METHOD OFPREPARINGFERRIC CARBOXYMALTOSE was granted on Aug 22, 2023.
2023-02-22
Formosalab receives TFDA approval for Eribulin Mesylate injectable
2022-12-08
TW Patent No. I784646 entitled METHOD FOR PREPARING FERRIC CARBOXYMALTOSE was granted on Nov 21, 2022.
2022-11-15
Formosa Labs' fermentation production line was successfully inspected by US FDA in November 2022.
2022-11-08
TW Patent No. I781345 entitled Crystalline form of Baricitinib and method for preparation thereof was granted on Oct 21, 2022.
2022-11-07
Formosa has won the Talent Quality-management System (TTQS) Bronze Medal Award.
2022-06-21
Formosa Injectable plant passed GMP/GDP inspection by TFDA.(Jun. 15, 2022)
2021-11-11
Passed GMP inspection by TFDA for packaging and labeling of medicinal products.
2021-06-01
US Patent No.US11,021,483 entitled Crystalline of camphorsulfonic acid salt of Rucaparib and method of preparing of tricyclic compounds, Rucaparib and crystalline of camphorsulfonic acid salt of Rucaparib was granted on June 1, 2021.
2021-02-26
TW Patent No. I718533 entitled PREPARATION METHOD OF RIBOCICLIB AND ITS SALT AND CRYSTALLINE FORM THEREOF was granted on Feb 11, 2021.
2020-09-30
US Patent No.US10766900B2 entitled Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof was granted on Sep 8, 2020.
2020-09-16
Formosa Labs and Fresenius Kabi enter into a Registration and Distribution Agreement for a breast cancer chemotherapy injection.
2020-09-01
TW Patent No. I703163 entitled Method for preparing Sugammadex Sodium and crystalline form thereof was granted on Sep 1, 2020.